HelloWorld Library

HelloWorldPatientView Library

CDCMMEClinicalConversionFactors Library

Common Routines Library

Common Logic Library

Common Configuration Library

OMTK Logic MK (2020) Library

OMTK Data (2020) Library

FHIR Helpers Library

FHIR ModelInfo Library

Common Logic Library for Recommendation #10 - Urine Drug Testing

Logic Library for Recommendation #1 (order-sign) - Nonpharmacologic and Nonopioid Pharmacologic Therapy Consideration

Logic Library for Recommendation #2 (order-sign) - Opioid Therapy Goals Discussion

Logic Library for Recommendation #3 (order-sign) - Opioid Immediate Release Form When Starting Opioid Therapy

Logic Library for Recommendations #4 and #5 (order-sign) - Lowest Effective Dose

Logic Library for Recommendation #6 (order-sign) - Prescribe Lowest Effective Dose and Duration

Logic Library for Recommendation #7 (order-sign) - Opioid Therapy Risk Assessment

Logic Library for Recommendation #8 (order-sign) - Naloxone Consideration

Logic Library for Recommendation #9 (order-sign) - Consider Patient’s History of Controlled Substance Prescriptions

Logic Library for Recommendation #10 (order-sign) - Urine Drug Testing

Logic Library for Recommendation #10 (patient-view) - Urine Drug Testing

Logic Library for Recommendation #11 (order-select) - Concurrent Use of Opioids and Benzodiazepines

Logic Library for Recommendation #11 (patient-view) - Concurrent Use of Opioids and Benzodiazepines

Logic Library for Recommendation #12 (patient-view) - Evidence-based Treatment for Patients with Opioid Use Disorder

An ActivityDefinition for recommendation of risk assessment

An ActivityDefinition for recommendation of urine screening

When prescribing opioids for subacute or chronic pain, providers should use urine drug testing before starting opioid therapy and consider urine drug testing at least annually to assess for prescribed medications as well as other controlled prescription drugs and illicit drugs.

When opioids are used for acute pain, clinicians should prescribe the lowest effective dose of immediate-release opioids and should prescribe no greater quantity than needed for the expected duration of pain severe enough to require opioids.

Clinicians should incorporate into the management plan strategies to mitigate risk, including considering offering naloxone when factors that increase risk for opioid overdose, such as history of overdose, history of substance use disorder, higher opioid dosages (≥50 MME/day), or concurrent benzodiazepine use, are present.

Clinicians should incorporate into the management plan strategies to mitigate risk, including considering offering naloxone when factors that increase risk for opioid overdose, such as history of overdose, history of substance use disorder, higher opioid dosages (≥50 MME/day), or concurrent benzodiazepine use, are present.

When prescribing opioids for subacute or chronic pain, providers should use urine drug testing before starting opioid therapy and consider urine drug testing at least annually to assess for prescribed medications as well as other controlled prescription drugs and illicit drugs.

When opioids are started, providers should prescribe the lowest effective dosage.

Clinicians should evaluate benefits and harms with patients within 1 to 4 weeks of starting opioid therapy for subacute or chronic pain or of dose escalation. Clinicians should evaluate benefits and harms of continued therapy with patients every 3 months or more frequently.

Nonpharmacologic therapy and nonopioid pharmacologic therapy are preferred for subacute or chronic pain.

When starting opioid therapy for subacute or chronic pain, clinicians should prescribe immediate-release opioids instead of extended-release/long-acting (ER/LA) opioids.

Nonpharmacologic therapy and nonopioid pharmacologic therapy are preferred for chronic pain.

Arrange evidence-based treatment (usually medication-assisted treatment with buprenorphine or methadone in combination with behavioral therapies) for patients with opioid use disorder.

Concurrently prescribing opioid medications with benzodiazepines increases the risk of harm for the patient.

Clinicians should review PDMP data when starting opioid therapy for subacute or chronic pain and periodically during opioid therapy for chronic pain.

Concurrently prescribing opioid medications with benzodiazepines increases the risk of harm for the patient.

When prescribing opioids for subacute or chronic pain, providers should use urine drug testing before starting opioid therapy and consider urine drug testing at least annually to assess for prescribed medications as well as other controlled prescription drugs and illicit drugs.

This library contains drug ingredient data for opioid ingredients of combinations drugs as determined using the RxNav API. The content was produced using the process described here.

This library contains logic to expose configurable conversion factors for the MME calculation functionality provided by the OMTKLogic library.

This library contains logic to surface the MME calculation functionality provided by the OMTKLogic library by extracting appropriate information from FHIR R4 MedicationRequest resource.

This library provides functionality for calculating Morphine Milligram Equivalents (MME) for opioid medications, as described in the CDC Opioid Prescribing Guideline.

Profile of CarePlan for use with 2022 CDC Clinical Practice Guideline

Profile of MedicationRequest for use with 2022 CDC Clinical Practice Guideline

Profile of Observation for decision support/quality metrics. Defines the core set of elements and extensions for quality rule and measure authors.

Profile of RequestGroup for use with 2022 CDC Clinical Practice Guideline

Profile of ValueSet for use with 2022 CDC Clinical Practice Guideline

Declares the DateLastUpdated and Frequency arguments to be used by the Data Date Roller for maintaining/rolling test data dates to keep them from going stale.

Describes the clinical focus for the ValueSet.

Describes the clinical focus for the ValueSet.

Describes the clinical focus for the ValueSet.

Describes the data element scope for the ValueSet.

Indicator value for CDS Hooks responses.

All opioid clinical drugs except those restricted to surgical use only, and that are in an extended release dose form code

Individual tests and panels of tests of urine for illicit drugs EXCEPT those for opioids.

Counseling and associated procedures for substance misuse

This value set contains concepts that represent patients receiving hospice care outside of a hospital or long term care facility.

Fentanyl and similar medications (sufentanil, alfentanil, remifentanil)

Urine tests, both quantitative and qualitative, including confirmatory, that detect Amphetamine-class drugs and metabolites

Procedure to assess the risk of opioid abuse occurring by a patient

All opioid clinical drugs except cough medications, antispasmodics, or those restricted to surgical use only as identified by those using an injectable form.

All neoplastic and malignant conditions, including pain due to neoplasm.

Cannabinoid, including synthetic and THC, urine tests

Urine tests to identify ethanol, metabolites, and disulfiram

NUCC oncology provider types who may provide encounters to patients with cancer

Sickle-cell disorders that cause painful crisis

All naloxone medications

A finding that documents a terminal prognosis

Presumed general urine tests for naturally occurring opioids (i.e. opiates) that are not specific to a particular substance based upon the inclusion of the word ‘opiates’ in the long name.

All benzodiazepine clinical drugs

Individual tests and panels of tests of urine for opioids

Urine tests to identify methadone and metabolites

Medication codes representing methadone medications

Problem list condition category.

Therapeutic activities indicating end of life. Include procedures or therapies specific to a terminal patient, exclude procedures or therapies performed on a deceased patient

Finding indicating that the Prescription Drug Monitoring Program (PDMP) data was reviewed

Any finding or condition that indicate problematic misuse of a substance other than tobacco or laxatives, including “history of” conditions.

Procedure codes for referral, admission, or transfer to a hospice

Medications potentially used in ambulatory setting that are CNS depressants but not contain an opioid class medication, and also do not contain cough medications or bowl transit modifiers.

Opioid medications that are not exclusively and solely derived from the opium plant. These are synthetic or semisynthetic opioids.

Medications derived from the opium plant that are not synthetically created . All metabolize to morphine.

Procedure Observation Category

US Core Health Concern Condition Category.

Encounter Diagnosis condition category.

Conditions associated with sleep-related breathing disorders.

Amphetamine class medications based upon the mapping of SNOMED CT drug class to ingredient then linked to RXNorm

A Pain medicine Plan of care note

Finding codes for receiving hospice care

Urine tests for naturally occurring opioids (i.e. opiates) that are specific to a particular naturally occurring opioid and therefore do not have the general word ‘opiates’ in the long name.

Urine tests for phencyclidine

Broad set of concepts that may represent a procedure to assess the risk of opioid abuse occurring by a patient

Procedure for subacute or chronic pain control management

Urine tests for synthetic and semi-synthetic (non-opiate) substances

Procedure for counseling on opioid use

Urine tests for fentanyl-type drugs and metabolites

Urine tests for cocaine and cocaine metabolites

The subject is currently experiencing the condition or situation, there is evidence of the condition or situation, or considered to be a significant risk.

Conditions indicating opioid misuse

Procedure for Prescription Drug Monitoring Program (PDMP) review

Medications considered to have an ingredient considered to be a CNS depressant, some of which may be mild. Removed from this set are cough medications and bowl transit modifiers.

Laboratory Observation Category

All Buprenorphine and Methadone medications

Codes specifying outpatient encounters

Conditions that generally are thought to have terminal prognosis

Indicates the urgency/importance of what this RequestGroup action conveys

CarePlan Example

Cancer Diagnosis Condition Example

End of Life Condition Example

Terminal Condition Example

Cancer Diagnosis Encounter Example

Oncology Participant Encounter Example

Ambulatory Opioid MedicationDispense Example

MedicationRequest Example

Ambulatory Opioid MedicationRequest Example

Observation Example

Patient Example

Oncology Specialist PractitionerRole Example

RequestGroup Example

Palliative Care ServiceRequest Example

A Device that represents a CQF Tooling version.